---
title: "Eli Lilly's orforglipron has reduced the weight of adult obesity patients by 11.2%"
description: "At the European Association for the Study of Diabetes meeting held in Vienna, Eli Lilly's weight loss drug orforglipron reduced the weight of obese adult patients by 11.2% in a large clinical trial. D"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/257614618.md"
published_at: "2025-09-16T22:04:45.000Z"
---

# Eli Lilly's orforglipron has reduced the weight of adult obesity patients by 11.2%

> At the European Association for the Study of Diabetes meeting held in Vienna, Eli Lilly's weight loss drug orforglipron reduced the weight of obese adult patients by 11.2% in a large clinical trial. Doctors stated that this achievement is significant for patients and will have a profound impact on the field of weight loss medications. The drug's side effects are consistent with currently available vaccines, and Eli Lilly also presented the full data from the major obesity trial at the meeting, which was published in the New England Journal of Medicine

Doctors said that in a large clinical trial, Eli Lilly's weight loss drug significantly reduced patients' weight, which is of great importance to patients and has a profound impact on the field.

At the European Association for the Study of Diabetes meeting held in Vienna, doctors reported that the American pharmaceutical company's tablet orforglipron reduced the weight of adult obese patients by 11.2%, and the side effects were consistent with currently available vaccines.

Eli Lilly presented the full data from the drug's main obesity trial at the conference and published it in the New England Journal of Medicine

### Related Stocks

- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元 | 礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元。 | [Link](https://longbridge.com/en/news/274805260.md) |
| 礼来公司（LLY）建立了价值 15 亿美元的减肥药库存 | 礼来（LLY）已准备好 15 亿美元的库存，以迎接其新减肥药 Orforglipron 预计在四月获得 FDA 批准。该公司计划在今夏推出该药，并进行大规模的营销活动，以与诺和诺德的 Wegovy 竞争。分析师对礼来的股票给予了一致的强烈买 | [Link](https://longbridge.com/en/news/276070062.md) |
| 如果 OpenAI 估值 8300 亿美元，那谷歌该值多少？ | OpenAI 最新融资估值约 8300 亿美元，约为 2027 年预期收入的 14 倍；而谷歌却仅约 6.7 倍。按倍数类比，谷歌与 OpenAI 之间存在约 2 倍的 “定价尺度差”。分析指出，市场过度放大了 AI 颠覆的风险，却忽视了谷 | [Link](https://longbridge.com/en/news/276509743.md) |
| DELL, SPOT, UNH：全球最大的对冲基金正在市场中寻找抄底机会 | 桥水基金（Bridgewater Associates），全球最大的对冲基金，管理资产达 1360 亿美元，在 2025 年第四季度对表现不佳的股票进行了重大投资，包括戴尔（DELL）、Spotify（SPOT）和联合健康（UnitedHe | [Link](https://longbridge.com/en/news/276384705.md) |
| 减肥药销量爆发！礼来 Q4 营收同比大增 43%，净利润增长 50%，2026 年营收指引 800 亿至 830 亿美元 \| 财报见闻 | 得益于 GLP-1 减肥药销量的爆发，礼来四季度营收、利润以及全年指引均超出市场预期。在减肥药双雄的巅峰对决中，礼来似乎已经给出了胜负的答案。诺和诺德此前警告称，受价格战加剧影响，今年销售额可能下滑 13%，而礼来却预计自身销售额将实现高达 | [Link](https://longbridge.com/en/news/274814398.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.